Clinical Trial Update: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Salanersen's (BIIB115) effects on movement and safety in people aged 15 to 60 with spinal muscular atrophy; open to those new …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Salanersen's (BIIB115) (BIIB115)

Snippet

Sponsor: Biogen | Conditions: Spinal Muscular Atrophy | Phase 3 | Status: RECRUITING